Cargando…

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report

RATIONALE: Regorafenib is an oral multikinase inhibitor and is approved as salvage therapy in the standard treatment of advanced colorectal cancer (CRC). Due to its limited efficacy, toxicity profile, and cost, it is necessary to identify those patients who may have the most benefit from regorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosati, Gerardo, Del Gaudio, Nunzio, Scarano, Enrico, Cifarelli, Rosa Anna, Altucci, Lucia, Bilancia, Domenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023677/ https://www.ncbi.nlm.nih.gov/pubmed/29924031 http://dx.doi.org/10.1097/MD.0000000000011178

Ejemplares similares

KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2016)

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report
por: Tang, Ronald, et al.
Publicado: (2015)

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
por: Rosati, Gerardo, et al.
Publicado: (2022)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
por: Dunbar, Erin M., et al.
Publicado: (2012)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer
por: Ebinç, Senar, et al.
Publicado: (2022)

The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options
por: Di Costanzo, Antonella, et al.
Publicado: (2020)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
por: Khan, Gazala, et al.
Publicado: (2014)

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib
por: Arai, Hiroyuki, et al.
Publicado: (2017)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
por: Aljubran, Ali, et al.
Publicado: (2019)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
por: Yoshino, Kenji, et al.
Publicado: (2017)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
por: Xu, Donghao, et al.
Publicado: (2022)

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
por: Lee, Dae-Won, et al.
Publicado: (2023)

Liver progenitor cell and KDR
por: Han, Songyan, et al.
Publicado: (2014)

Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials
por: Rosati, Gerardo, et al.
Publicado: (2019)

KDM4 Involvement in Breast Cancer and Possible Therapeutic Approaches
por: Varghese, Benluvankar, et al.
Publicado: (2021)

Regorafenib with or without a programmed cell death protein 1 antibody as third‐line treatment for microsatellite stable metastatic colorectal cancer
por: He, Wen‐Zhuo, et al.
Publicado: (2022)

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
por: Giampieri, Riccardo, et al.
Publicado: (2016)

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
por: Belli, Valentina, et al.
Publicado: (2017)

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
por: Calcagno, Fabien, et al.
Publicado: (2016)

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
por: Novakova-Jiresova, Alena, et al.
Publicado: (2020)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
por: Kato, Takeshi, et al.
Publicado: (2023)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
por: Lin, Chun-Yu, et al.
Publicado: (2018)

Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series
por: Leal, José Luis, et al.
Publicado: (2018)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_122iup7fjnm7mqvkirann4jr0d